{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:14Z","timestamp":1791994574740,"version":"4.4.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02292-3","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:25:12Z","timestamp":1771835112000},"page":"485-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Autoimmune Bullous Diseases: Therapeutic Update"],"prefix":"10.1007","volume":"86","author":[{"given":"Michael","family":"Kasperkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"2292_CR1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"11","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primers. 2017;11(3):17026.","journal-title":"Nat Rev Dis Primers"},{"issue":"10201","key":"2292_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"E Schmidt","year":"2019","unstructured":"Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882\u201394.","journal-title":"Lancet"},{"issue":"9863","key":"2292_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332.","journal-title":"Lancet"},{"issue":"1","key":"2292_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers. 2025;11(1):12.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2292_CR5","first-page":"405","volume":"21","author":"MM Holtsche","year":"2023","unstructured":"Holtsche MM, Boch K, Schmidt E. Autoimmune bullous dermatoses. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2023;21(4):405\u201312.","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"24","key":"2292_CR6","first-page":"413","volume":"118","author":"NV Beek","year":"2021","unstructured":"Beek NV, Zillikens D, Schmidt E. Bullous autoimmune dermatoses\u2014clinical features, diagnostic evaluation, and treatment options. Dtsch Arztebl Int. 2021;118(24):413\u201320.","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"2292_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/13543784.2023.2242778","volume":"32","author":"H Olbrich","year":"2023","unstructured":"Olbrich H, Sadik CD, Schmidt E. Autoimmune blistering diseases: promising agents in clinical trials. Expert Opin Investig Drugs. 2023;32(7):615\u201323.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2292_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100004","volume":"1","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021;1(1):100004.","journal-title":"JID Innov"},{"key":"2292_CR9","doi-asserted-by":"crossref","unstructured":"Joly P, Horwath B, Patsatsi A, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900\u201313.","DOI":"10.1111\/jdv.16752"},{"key":"2292_CR10","doi-asserted-by":"publisher","unstructured":"Marschall J, Schierhofer LIA, Santos AMS, Hinterseher J, Berg BB, Mobs C, et al. Deep analysis of desmoglein-3-reactive CD4(+) T cells in pemphigus vulgaris reveals a type 17\/Type 2 T-cell signature. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.08.039.","DOI":"10.1016\/j.jid.2025.08.039"},{"key":"2292_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.701809","volume":"8","author":"T Schmitt","year":"2021","unstructured":"Schmitt T, Waschke J. Autoantibody-specific signalling in pemphigus. Front Med. 2021;8:701809.","journal-title":"Front Med"},{"key":"2292_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563286","volume":"16","author":"X Lin","year":"2025","unstructured":"Lin X, Li X, Zhai Z, Zhang M. JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2025;16:1563286.","journal-title":"Front Immunol"},{"key":"2292_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103128","volume":"142","author":"C Xu","year":"2024","unstructured":"Xu C, Zhang T, Wang H, Zhu L, Ruan Y, Huang Z, et al. Integrative single-cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus. J Autoimmun. 2024;142:103128.","journal-title":"J Autoimmun"},{"key":"2292_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00485","volume":"9","author":"F Vielmuth","year":"2018","unstructured":"Vielmuth F, Spindler V, Waschke J. Atomic force microscopy provides new mechanistic insights into the pathogenesis of pemphigus. Front Immunol. 2018;9:485.","journal-title":"Front Immunol"},{"key":"2292_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884067","volume":"13","author":"DT Egu","year":"2022","unstructured":"Egu DT, Schmitt T, Waschke J. Mechanisms causing acantholysis in pemphigus-lessons from human skin. Front Immunol. 2022;13:884067.","journal-title":"Front Immunol"},{"issue":"22","key":"2292_CR16","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1111\/bph.15233","volume":"177","author":"IAK Burmester","year":"2020","unstructured":"Burmester IAK, Flaswinkel S, Thies CS, Kasprick A, Kamaguchi M, Bumiller-Bini V, et al. Identification of novel therapeutic targets for blocking acantholysis in pemphigus. Br J Pharmacol. 2020;177(22):5114\u201330.","journal-title":"Br J Pharmacol"},{"key":"2292_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169947","volume":"14","author":"S Emtenani","year":"2023","unstructured":"Emtenani S, Hertl M, Schmidt E, Hudemann C. Mouse models of pemphigus: valuable tools to investigate pathomechanisms and novel therapeutic interventions. Front Immunol. 2023;14:1169947.","journal-title":"Front Immunol"},{"key":"2292_CR18","doi-asserted-by":"crossref","unstructured":"Schmidt E, Sticherling M, Sardy M, Eming R, Goebeler M, Hertl M, et al. S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges. 2020;18(5):516\u201326.","DOI":"10.1111\/ddg.14097"},{"issue":"1","key":"2292_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaad.2020.08.028","volume":"85","author":"MS Lee","year":"2021","unstructured":"Lee MS, Yeh YC, Tu YK, Chan TC. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2021;85(1):176\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2292_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s12325-025-03118-6","volume":"42","author":"C Le Reun","year":"2025","unstructured":"Le Reun C, Yasmeen N, Cullen AE, Sawyer L, Ostrovskaya O, Barion F. Comparability of randomized controlled trials evaluating pharmacological interventions for pemphigus vulgaris and pemphigus foliaceus: a systematic mapping review. Adv Ther. 2025;42(4):1642\u201391.","journal-title":"Adv Ther"},{"issue":"4","key":"2292_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","volume":"16","author":"D Meyersburg","year":"2012","unstructured":"Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial. 2012;16(4):311\u201320.","journal-title":"Ther Apher Dial"},{"issue":"5","key":"2292_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bjd\/ljad489","volume":"190","author":"N van Beek","year":"2024","unstructured":"van Beek N, Eming R, Reuss A, Zillikens D, Sardy M, Gunther C, et al. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. Br J Dermatol. 2024;190(5):657\u201367.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2292_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","volume":"166","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154\u201360.","journal-title":"Br J Dermatol"},{"key":"2292_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2292_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.20431","volume":"185","author":"DF Murrell","year":"2021","unstructured":"Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II believe study. Br J Dermatol. 2021;185(4):745\u201355.","journal-title":"Br J Dermatol"},{"issue":"8","key":"2292_CR26","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","volume":"144","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, et al. Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study. J Invest Dermatol. 2024;144(8):1762-71 e6.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2292_CR27","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jid.2024.03.014","volume":"144","author":"AS Payne","year":"2024","unstructured":"Payne AS, Manfredo Vieira S. Bruton\u2019s tyrosine kinase inhibition in pemphigus: an embattled frontier. J Invest Dermatol. 2024;144(8):1667\u201370.","journal-title":"J Invest Dermatol"},{"issue":"2-3","key":"2292_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","volume":"38","author":"N Ishii","year":"2010","unstructured":"Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol. 2010;38(2\u20133):186\u201395.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"2292_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2292_CR30","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","volume":"141","author":"VP Werth","year":"2021","unstructured":"Werth VP, Culton DA, Concha JSS, Graydon JS, Blumberg LJ, Okawa J, et al. Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus. J Invest Dermatol. 2021;141(12):2858-65 e4.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2292_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Csorgo Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186(3):429\u201339.","journal-title":"Br J Dermatol"},{"key":"2292_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095","volume":"13","author":"M Maho-Vaillant","year":"2022","unstructured":"Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13:863095.","journal-title":"Front Immunol"},{"issue":"7","key":"2292_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"2292_CR34","unstructured":"Joly P MD, Aoyama Y, Caux F, De D, Flouri M, Goebeler M, Ji C, Kiritsi D, Pan M, Patsatsi A, Schmidt E, Vassileva S, Stoykov I, Verheesen P, Werth VP, Hall RP, The ADDRESS Investigator Study Group. Efficacy and safety of subcutaneous efgartigimod in moderate to severe pemphigus (ADDRESS): a phase 3, randomized, double-blind trial. Br J Dermatol. (in preparation)."},{"issue":"5","key":"2292_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill JC, Reynaud CA, Mahevas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int. 2020;97(5):885\u201393.","journal-title":"Kidney Int"},{"issue":"3","key":"2292_CR36","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1111\/jdv.20245","volume":"39","author":"J Mao","year":"2025","unstructured":"Mao J, Bao S, Chen Y, Zhuang Z, Chen W, Li G, et al. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi-centre cohort study. J Eur Acad Dermatol Venereol. 2025;39(3):e244\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2292_CR37","first-page":"1338","volume":"17","author":"M Rapp","year":"2018","unstructured":"Rapp M, Pentland A, Richardson C. Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol. 2018;17(12):1338\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"2292_CR38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jdcr.2020.05.034","volume":"6","author":"DM Klufas","year":"2020","unstructured":"Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020;6(8):734\u20136.","journal-title":"JAAD Case Rep"},{"issue":"7","key":"2292_CR39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/1346-8138.17108","volume":"51","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xiao Y, Li X, Wang J, Zhou X, Wang Y, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab. J Dermatol. 2024;51(7):1026\u201330.","journal-title":"J Dermatol"},{"issue":"12","key":"2292_CR40","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","volume":"150","author":"CT Ellebrecht","year":"2014","unstructured":"Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150(12):1331\u20135.","journal-title":"JAMA Dermatol"},{"key":"2292_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2021.08.005","volume":"16","author":"G Benesh","year":"2021","unstructured":"Benesh G, Andriano TM, Cohen SR. Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Rep. 2021;16:12\u20135.","journal-title":"JAAD Case Rep"},{"issue":"9","key":"2292_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19133","volume":"37","author":"E de-la-Rosa-Fernandez","year":"2023","unstructured":"de-la-Rosa-Fernandez E, Loizate-Sarrionandia I, Gonzalez-Rodriguez J, Herrero-Moyano M, Fernandez-de-Misa-Cabrera R, Suarez-Hernandez J. Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management. J Eur Acad Dermatol Venereol. 2023;37(9):e1104-e6.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2292_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","volume":"64","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Tian J, Xiao F, Zheng L, Zhu X, Wu L, et al. B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine Growth Factor Rev. 2022;64:57\u201370.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"2292_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","volume":"103","author":"J Yamagami","year":"2021","unstructured":"Yamagami J, Ujiie H, Aoyama Y, Ishii N, Tateishi C, Ishiko A, et al. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus. J Dermatol Sci. 2021;103(3):135\u201342.","journal-title":"J Dermatol Sci"},{"issue":"17","key":"2292_CR45","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: game changer or stepping stone? Blood. 2025;145(17):1841\u20139.","journal-title":"Blood"},{"issue":"6295","key":"2292_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179\u201384.","journal-title":"Science"},{"issue":"15","key":"2292_CR47","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMcibr1608900","volume":"375","author":"M Amagai","year":"2016","unstructured":"Amagai M. Modulating immunity to treat autoimmune disease. N Engl J Med. 2016;375(15):1487\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"2292_CR48","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130(12):6317\u201324.","journal-title":"J Clin Invest"},{"issue":"2","key":"2292_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100339","volume":"5","author":"M Karakioulaki","year":"2025","unstructured":"Karakioulaki M, Dunn P, Murrell DF, Payne A, Schmidt E, Werth V, et al. Advances in pemphigus and pemphigoid: a report of the international meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece. JID Innov. 2025;5(2):100339.","journal-title":"JID Innov."},{"issue":"4","key":"2292_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1515\/rir-2024-0029","volume":"5","author":"H Huang","year":"2024","unstructured":"Huang H, Wei X. Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases. Rheumatol Immunol Res. 2024;5(4):209\u201316.","journal-title":"Rheumatol Immunol Res"},{"key":"2292_CR51","doi-asserted-by":"publisher","first-page":"1407871","DOI":"10.3389\/fphar.2024.1407871","volume":"15","author":"T Fan","year":"2024","unstructured":"Fan T, Wang W, Wang Y, Zeng M, Liu Y, Zhu S, et al. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol. 2024;15:1407871.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2292_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-022-35741-0","volume":"14","author":"AM Sigmund","year":"2023","unstructured":"Sigmund AM, Winkler M, Engelmayer S, Kugelmann D, Egu DT, Steinert LS, et al. Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus. Nat Commun. 2023;14(1):116.","journal-title":"Nat Commun"},{"key":"2292_CR53","doi-asserted-by":"crossref","unstructured":"Sigmund AM, Bayerbach FC, Kugelmann D, Butz E, Moztarzadeh S, Schikora ME, et al. Epac1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion. JCI Insight. 2025;10(10):e187481.","DOI":"10.1172\/jci.insight.187481"},{"key":"2292_CR54","doi-asserted-by":"crossref","unstructured":"Alhasawi RH, Shaheen EA, Alshabanat NM, Brashi R, Ahmed WA, Alqahtani SH, et al. The efficacy of apremilast in pemphigus: a systematic review of case reports. Dermatol Reports. 2025;17(4):10245.","DOI":"10.4081\/dr.2025.10245"},{"issue":"2","key":"2292_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","volume":"46","author":"L Chikhoune","year":"2025","unstructured":"Chikhoune L, Poggi C, Moreau J, Dubucquoi S, Hachulla E, Collet A, et al. JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Med Interne. 2025;46(2):89\u2013106.","journal-title":"Rev Med Interne"},{"issue":"2","key":"2292_CR56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12026-020-09122-y","volume":"68","author":"K Juczynska","year":"2020","unstructured":"Juczynska K, Wozniacka A, Waszczykowska E, Danilewicz M, Wagrowska-Danilewicz M, Zebrowska A. Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris. Immunol Res. 2020;68(2):97\u2013103.","journal-title":"Immunol Res"},{"key":"2292_CR57","doi-asserted-by":"crossref","unstructured":"Ociepa K, Danilewicz M, Wagrowska-Danilewicz M, Peterson-Jeckowska R, Wojcicka-Rubin A, Lewkowicz N, et al. Expression of the selected proteins of JAK\/STAT signaling pathway in diseases with oral mucosa involvement. Int J Mol Sci. 2022;24(1):323.","DOI":"10.3390\/ijms24010323"},{"issue":"12","key":"2292_CR58","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14740338.2023.2248872","volume":"22","author":"L Wang","year":"2023","unstructured":"Wang L, Zhao B. Janus kinase inhibitor-tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data. Expert Opin Drug Saf. 2023;22(12):1317\u201320.","journal-title":"Expert Opin Drug Saf"},{"key":"2292_CR59","doi-asserted-by":"crossref","unstructured":"Didona D, Hudemann C, Garn H, Krzikalla D, Wang SH, Hinterseher J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigus. Br J Dermatol. 2026;194(1):86\u201398.","DOI":"10.1093\/bjd\/ljaf311"},{"key":"2292_CR60","doi-asserted-by":"crossref","unstructured":"Rujitharanawong C, Payne AS. Immunoregulatory effects of TPM203 peptide-nanoparticle therapy in pemphigus vulgaris. Br J Dermatol. 2026;194(1):6\u20137.","DOI":"10.1093\/bjd\/ljaf323"},{"key":"2292_CR61","doi-asserted-by":"publisher","first-page":"1193032","DOI":"10.3389\/fimmu.2023.1193032","volume":"14","author":"R Lotti","year":"2023","unstructured":"Lotti R, Hundt JE, Ludwig RJ, Hammers CM, Bennett B, Amato A, et al. Blocking soluble FAS ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. Front Immunol. 2023;14:1193032.","journal-title":"Front Immunol"},{"issue":"5-6","key":"2292_CR62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/17512433.2024.2350943","volume":"17","author":"A Vafaeian","year":"2024","unstructured":"Vafaeian A, Mahmoudi H, Daneshpazhooh M. What is novel in the clinical management of pemphigus vulgaris? Expert Rev Clin Pharmacol. 2024;17(5\u20136):489\u2013503.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"2292_CR63","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998\u20132004.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2292_CR64","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/jdv.17107","volume":"35","author":"N van Beek","year":"2021","unstructured":"van Beek N, Weidinger A, Schneider SW, Kleinheinz A, Glaser R, Holtsche MM, et al. Incidence of pemphigoid diseases in Northern Germany in 2016\u2014first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol. 2021;35(5):1197\u2013202.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2292_CR65","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"2292_CR66","unstructured":"Schmidt E, Groves R. Immunobullous disorders. In: Griffith C, Barker J, Bleiker T, Hussain W, Simposn RS, editors. Rook's textbook of dermatology, part 3, chapter 50, 10th edition, vol 2. Chichester: Wiley-Blackwell; 2024. p. 50.1-.61."},{"issue":"5","key":"2292_CR67","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","volume":"78","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989-95 e2.","journal-title":"J Am Acad Dermatol"},{"key":"2292_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363032","volume":"15","author":"N van Beek","year":"2024","unstructured":"van Beek N, Holtsche MM, Atefi I, Olbrich H, Schmitz MJ, Pruessmann J, et al. State-of-the-art diagnosis of autoimmune blistering diseases. Front Immunol. 2024;15:1363032.","journal-title":"Front Immunol"},{"issue":"2","key":"2292_CR69","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174\u20138.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2292_CR70","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92(5):2480\u20138.","journal-title":"J Clin Invest"},{"issue":"3","key":"2292_CR71","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","volume":"13","author":"W Nishie","year":"2007","unstructured":"Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR, et al. Humanization of autoantigen. Nat Med. 2007;13(3):378\u201383.","journal-title":"Nat Med"},{"issue":"2","key":"2292_CR72","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/path.6220","volume":"262","author":"M Pigors","year":"2024","unstructured":"Pigors M, Patzelt S, Reichhelm N, Dworschak J, Khil\u2019chenko S, Emtenani S, et al. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade. J Pathol. 2024;262(2):161\u201374.","journal-title":"J Pathol"},{"issue":"8","key":"2292_CR73","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","volume":"184","author":"FS Schulze","year":"2014","unstructured":"Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Kohl J, et al. Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol. 2014;184(8):2185\u201396.","journal-title":"Am J Pathol"},{"issue":"5","key":"2292_CR74","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","volume":"166","author":"IM Blocker","year":"2012","unstructured":"Blocker IM, Dahnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, et al. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol. 2012;166(5):964\u201370.","journal-title":"Br J Dermatol"},{"key":"2292_CR75","doi-asserted-by":"crossref","unstructured":"Emtenani S, Linnemann BE, Recke A, von Georg A, Goletz S, Schmidt E, et al. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity. J Dermatol Sci. 2024;114(2):64\u201370.","DOI":"10.1016\/j.jdermsci.2024.03.009"},{"issue":"6","key":"2292_CR76","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","volume":"142","author":"S Haeberle","year":"2018","unstructured":"Haeberle S, Wei X, Bieber K, Goletz S, Ludwig RJ, Schmidt E, et al. Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. J Allergy Clin Immunol. 2018;142(6):1831-42 e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2292_CR77","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1007\/s12325-024-02992-w","volume":"41","author":"VP Werth","year":"2024","unstructured":"Werth VP, Murrell DF, Joly P, Heck R, Orengo JM, Ardeleanu M, et al. Pathophysiology of bullous pemphigoid: role of type 2 inflammation and emerging treatment strategies (narrative review). Adv Ther. 2024;41(12):4418\u201332.","journal-title":"Adv Ther"},{"key":"2292_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128154","volume":"10","author":"R Maglie","year":"2023","unstructured":"Maglie R, Solimani F, Didona D, Pipito C, Antiga E, Di Zenzo G. The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets. Front Med (Lausanne). 2023;10:1128154.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2292_CR79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","volume":"129","author":"H Iwata","year":"2009","unstructured":"Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol. 2009;129(4):919\u201326.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2292_CR80","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","volume":"115","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP, et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol. 2000;115(5):842\u20138.","journal-title":"J Invest Dermatol"},{"key":"2292_CR81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM, Kunstner A, Goletz S, Petersen BS, Thaci D, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104\u201312.","journal-title":"J Autoimmun"},{"issue":"12","key":"2292_CR82","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","volume":"134","author":"S Le Jan","year":"2014","unstructured":"Le Jan S, Plee J, Vallerand D, Dupont A, Delanez E, Durlach A, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol. 2014;134(12):2908\u201317.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2292_CR83","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu T, Wang Z, Xue X, Zhang Y, Mi Z, Zhao Q, et al. Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nat Commun. 2024;15(1):5949.","journal-title":"Nat Commun"},{"issue":"8","key":"2292_CR84","first-page":"CD002292","volume":"8","author":"S Singh","year":"2023","unstructured":"Singh S, Kirtschig G, Anchan VN, Chi CC, Taghipour K, Boyle RJ, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2023;8(8):CD002292.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2292_CR85","first-page":"305","volume":"153","author":"E Cozzani","year":"2018","unstructured":"Cozzani E, Marzano AV, Caproni M, Feliciani C, Calzavara-Pinton P. Bullous pemphigoid: Italian guidelines adapted from the EDF\/EADV guidelines. G Ital Dermatol Venereol. 2018;153(3):305\u201315.","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"2292_CR86","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"VA Venning","year":"2012","unstructured":"Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200\u201314.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2292_CR87","first-page":"516","volume":"18","author":"E Schmidt","year":"2020","unstructured":"Schmidt E, Sticherling M, Sardy M, Eming R, Goebeler M, Hertl M, et al. S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges. 2020;18(5):516\u201326.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"2292_CR88","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1346-8138.15111","volume":"46","author":"H Ujiie","year":"2019","unstructured":"Ujiie H, Iwata H, Yamagami J, Nakama T, Aoyama Y, Ikeda S, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019;46(12):1102\u201335.","journal-title":"J Dermatol"},{"issue":"3","key":"2292_CR89","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annder.2011.01.009","volume":"138","author":"P Bernard","year":"2011","unstructured":"Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S, Joly P. [Bullous pemphigoid. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de Dermatologie]. Ann Dermatol Venereol. 2011;138(3):247\u201351.","journal-title":"Ann Dermatol Venereol"},{"issue":"10","key":"2292_CR90","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 k guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689\u2013704.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2292_CR91","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137.","journal-title":"N Engl J Med"},{"issue":"10079","key":"2292_CR92","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630\u20138.","journal-title":"Lancet"},{"issue":"5","key":"2292_CR93","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, Glaser R, Hertl M, Pfeiffer C, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299\u2013305.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2292_CR94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017;85(2):77\u201384.","journal-title":"J Dermatol Sci"},{"issue":"9","key":"2292_CR95","first-page":"1109","volume":"16","author":"F Hubner","year":"2018","unstructured":"Hubner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hubner J, Sufke S, et al. Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges. 2018;16(9):1109\u201318.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"2292_CR96","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","volume":"71","author":"M Kasperkiewicz","year":"2014","unstructured":"Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D, et al. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol. 2014;71(5):1018\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2292_CR97","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","volume":"81","author":"M Polansky","year":"2019","unstructured":"Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2292_CR98","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjd.19890","volume":"185","author":"DS Yoo","year":"2021","unstructured":"Yoo DS, Lee JH, Kim SC, Kim JH. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Br J Dermatol. 2021;185(1):210\u20132.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2292_CR99","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1038\/s41598-019-40203-7","volume":"9","author":"N Berkani","year":"2019","unstructured":"Berkani N, Joly P, Golinski ML, Colliou N, Lim A, Larbi A, et al. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019;9(1):3525.","journal-title":"Sci Rep"},{"issue":"2","key":"2292_CR100","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/bjd\/ljad369","volume":"190","author":"R Chebani","year":"2024","unstructured":"Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024;190(2):258\u201365.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2292_CR101","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2292_CR102","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","volume":"20","author":"N Kremer","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, Hodak E, Mimouni D, Lapidoth M, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209\u201316.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2292_CR103","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol. 2024;25(2):195\u2013212.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2292_CR104","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","volume":"32","author":"FJ Munoz-Bellido","year":"2022","unstructured":"Munoz-Bellido FJ, Moreno E, Davila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97\u2013115.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"2292_CR105","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","volume":"41","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, et al. Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024;41(7):2991\u20133002.","journal-title":"Adv Ther"},{"key":"2292_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.10.004","author":"M Thapa","year":"2025","unstructured":"Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025. https:\/\/doi.org\/10.1016\/j.jdin.2025.10.004.","journal-title":"JAAD Int"},{"issue":"3","key":"2292_CR107","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon D, Yousefi S, Cazzaniga S, Burgler C, Radonjic S, Houriet C, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669\u201372.","journal-title":"Allergy"},{"issue":"4","key":"2292_CR108","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","volume":"95","author":"Z Liu","year":"1995","unstructured":"Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest. 1995;95(4):1539\u201344.","journal-title":"J Clin Invest"},{"issue":"11","key":"2292_CR109","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1172\/JCI17891","volume":"116","author":"KC Nelson","year":"2006","unstructured":"Nelson KC, Zhao M, Schroeder PR, Li N, Wetsel RA, Diaz LA, et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest. 2006;116(11):2892\u2013900.","journal-title":"J Clin Invest"},{"key":"2292_CR110","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","volume":"9","author":"CM Karsten","year":"2018","unstructured":"Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze FS, et al. Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol. 2018;9:488.","journal-title":"Front Immunol"},{"issue":"6","key":"2292_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100307","volume":"4","author":"T Passeron","year":"2024","unstructured":"Passeron T, Fontas E, Boye T, Richard MA, Delaporte E, Dereure O. Treatment of bullous pemphigoid with avdoralimab: multicenter, randomized, open-labeled phase 2 study. JID Innov. 2024;4(6):100307.","journal-title":"JID Innov"},{"issue":"5","key":"2292_CR112","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","volume":"137","author":"T Sezin","year":"2017","unstructured":"Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K, et al. The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. J Invest Dermatol. 2017;137(5):1104\u201313.","journal-title":"J Invest Dermatol"},{"key":"2292_CR113","doi-asserted-by":"crossref","unstructured":"Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, et al. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019;4(15):e128239.","DOI":"10.1172\/jci.insight.128239"},{"issue":"6","key":"2292_CR114","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","volume":"158","author":"CD Sadik","year":"2022","unstructured":"Sadik CD, Rashid H, Hammers CM, Diercks GFH, Weidinger A, Beissert S, et al. Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial. JAMA Dermatol. 2022;158(6):641\u20139.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2292_CR115","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","volume":"139","author":"PC Freire","year":"2019","unstructured":"Freire PC, Munoz CH, Derhaschnig U, Schoergenhofer C, Firbas C, Parry GC, et al. Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. J Invest Dermatol. 2019;139(12):2417-24 e2.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2292_CR116","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","volume":"18","author":"EH Kowalski","year":"2019","unstructured":"Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526\u201334.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2292_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jid.2022.07.019","volume":"143","author":"O Lindgren","year":"2023","unstructured":"Lindgren O, Le Menn G, Tuusa J, Chen ZJ, Tasanen K, Kokkonen N. Absence of NC14A domain of COLXVII\/BP180 in mice results in IL-17-associated skin inflammation. J Invest Dermatol. 2023;143(1):48-56 e7.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2292_CR118","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00403-025-04052-x","volume":"317","author":"N Heidari","year":"2025","unstructured":"Heidari N, Hosseini S, Heidari A, Ghane Y, Daneshpazhooh M, Mahmoudi H. A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects. Arch Dermatol Res. 2025;317(1):544.","journal-title":"Arch Dermatol Res"},{"issue":"12","key":"2292_CR119","first-page":"1478","volume":"18","author":"MM Holtsche","year":"2020","unstructured":"Holtsche MM, Hammers CM, Chakievska L, Ludwig RJ, Thaci D, Zillikens D, et al. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. J Dtsch Dermatol Ges. 2020;18(12):1478\u201380.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2292_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1148660","volume":"10","author":"K Drenovska","year":"2023","unstructured":"Drenovska K, Valeva E, Shahid M, Vassileva S. Case report: coexistence of bullous pemphigoid and psoriasis: therapeutic challenge and IL17A-targeted parallel treatment strategy. Front Med. 2023;10:1148660.","journal-title":"Front Med"},{"issue":"6","key":"2292_CR121","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1111\/jdv.18907","volume":"37","author":"K Bakirtzi","year":"2023","unstructured":"Bakirtzi K, Sotiriou E, Papadimitriou I, Vakirlis E, Delli FS, Ioannides D. Anti-interleukin-17A biologics for the long-term treatment of bullous pemphigoid: a prospective, cohort study. J Eur Acad Dermatol Venereol. 2023;37(6):e749\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2292_CR122","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","volume":"31","author":"J Loget","year":"2017","unstructured":"Loget J, Plee J, Antonicelli F, Bernard P. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2292_CR123","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1111\/jdv.19317","volume":"37","author":"C Cole","year":"2023","unstructured":"Cole C, Amber KT. Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL-23 inhibition. J Eur Acad Dermatol Venereol. 2023;37(11):e1339\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2292_CR124","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-023-08973-1","volume":"65","author":"HC Chen","year":"2023","unstructured":"Chen HC, Wang CW, Toh WH, Lee HE, Chung WH, Chen CB. Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches. Clin Rev Allergy Immunol. 2023;65(3):331\u201353.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2292_CR125","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ced\/llad331","volume":"49","author":"R Maglie","year":"2024","unstructured":"Maglie R, Baffa ME, Senatore S, Pipito C, Caproni M, Solimani F, et al. Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease. Clin Exp Dermatol. 2024;49(2):161\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2292_CR126","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/bjd\/ljaf035","volume":"192","author":"R Maglie","year":"2025","unstructured":"Maglie R, Didona D, Solimani F, Pipito C, Baffa ME, Hertl M, et al. Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series. Br J Dermatol. 2025;192(6):1124\u20136.","journal-title":"Br J Dermatol"},{"issue":"11","key":"2292_CR127","first-page":"1476","volume":"23","author":"M Wittenberg","year":"2025","unstructured":"Wittenberg M, Solimani F, Dilling A, Snobar R, Ghoreschi K, Klemp M, et al. Treatment of juvenile bullous pemphigoid with lebrikizumab. J Dtsch Dermatol Ges. 2025;23(11):1476\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"2292_CR128","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354.","journal-title":"Am J Clin Dermatol"},{"key":"2292_CR129","doi-asserted-by":"crossref","unstructured":"Pruessmann J, Pruessmann W, Holtsche MM, Linnemann B, Hammers CM, van Beek N, et al. Immunomodulator galectin-9 is increased in blood and skin of patients with bullous pemphigoid. Acta Derm Venereol. 2021;101(3):adv00419.","DOI":"10.2340\/00015555-3771"},{"issue":"1","key":"2292_CR130","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","volume":"105","author":"Z Liu","year":"2000","unstructured":"Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105(1):113\u201323.","journal-title":"J Clin Invest"},{"issue":"4","key":"2292_CR131","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI23977","volume":"115","author":"Z Liu","year":"2005","unstructured":"Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest. 2005;115(4):879\u201387.","journal-title":"J Clin Invest"},{"issue":"3","key":"2292_CR132","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1084\/jem.188.3.475","volume":"188","author":"Z Liu","year":"1998","unstructured":"Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med. 1998;188(3):475\u201382.","journal-title":"J Exp Med"},{"issue":"5","key":"2292_CR133","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/path.1674","volume":"204","author":"I Shimanovich","year":"2004","unstructured":"Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Brocker EB, Opdenakker G, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol. 2004;204(5):519\u201327.","journal-title":"J Pathol"},{"issue":"1","key":"2292_CR134","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41467-020-20604-3","volume":"12","author":"S Hiroyasu","year":"2021","unstructured":"Hiroyasu S, Zeglinski MR, Zhao H, Pawluk MA, Turner CT, Kasprick A, et al. Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nat Commun. 2021;12(1):302.","journal-title":"Nat Commun"},{"issue":"9","key":"2292_CR135","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.jid.2018.03.1499","volume":"138","author":"X Yu","year":"2018","unstructured":"Yu X, Akbarzadeh R, Pieper M, Scholzen T, Gehrig S, Schultz C, et al. Neutrophil adhesion is a prerequisite for antibody-mediated proteolytic tissue damage in experimental models of epidermolysis bullosa acquisita. J Invest Dermatol. 2018;138(9):1990\u20138.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2292_CR136","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269\u201379.","journal-title":"Allergy"},{"key":"2292_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.942493","volume":"13","author":"S Emtenani","year":"2022","unstructured":"Emtenani S, Holtsche MM, Stahlkopf R, Seiler DL, Burn T, Liu H, et al. Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients. Front Immunol. 2022;13:942493.","journal-title":"Front Immunol"},{"issue":"8","key":"2292_CR138","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM197802232980803","volume":"298","author":"BU Wintroub","year":"1978","unstructured":"Wintroub BU, Mihm MC Jr, Goetzl EJ, Soter NA, Austen KF. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med. 1978;298(8):417\u201321.","journal-title":"N Engl J Med"},{"issue":"10","key":"2292_CR139","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.jid.2024.02.029","volume":"144","author":"Y Ruan","year":"2024","unstructured":"Ruan Y, Xu C, Zhang T, Zhu L, Wang H, Wang J, et al. Single-cell profiling unveils the inflammatory heterogeneity within cutaneous lesions of bullous pemphigoid. J Invest Dermatol. 2024;144(10):2176-86 e6.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2292_CR140","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","volume":"108","author":"R Chen","year":"2001","unstructured":"Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, Werb Z, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108(8):1151\u20138.","journal-title":"J Clin Invest"},{"issue":"43","key":"2292_CR141","doi-asserted-by":"publisher","first-page":"37358","DOI":"10.1074\/jbc.M111.272401","volume":"286","author":"L Lin","year":"2011","unstructured":"Lin L, Bankaitis E, Heimbach L, Li N, Abrink M, Pejler G, et al. Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid. J Biol Chem. 2011;286(43):37358\u201367.","journal-title":"J Biol Chem"},{"issue":"5","key":"2292_CR142","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2018","unstructured":"Lin L, Hwang BJ, Culton DA, Li N, Burette S, Koller BH, et al. Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol. 2018;138(5):1032\u201343.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2292_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.70","volume":"2","author":"S Nsiah-Dosu","year":"2022","unstructured":"Nsiah-Dosu S, Scholz C, Orinska Z, Sadik CD, Ludwig RJ, Schmidt E, et al. Mast cell-deficient mice Mcpt5Cre\/Dicer (fl\/fl) redefine the role of mast cells in experimental bullous pemphigoid. Skin Health Dis. 2022;2(1):e70.","journal-title":"Skin Health Dis"},{"key":"2292_CR144","doi-asserted-by":"crossref","unstructured":"Zhang Y, Hwang BJ, Liu Z, Li N, Lough K, Williams SE, et al. BP180 dysfunction triggers spontaneous skin inflammation in mice. Proc Natl Acad Sci U S A. 2018;115(25):6434\u201339.","DOI":"10.1073\/pnas.1721805115"},{"key":"2292_CR145","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4594630","volume":"2020","author":"SZ Li","year":"2020","unstructured":"Li SZ, Jin XX, Ge XL, Zuo YG, Jin HZ. Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells. J Immunol Res. 2020;2020:4594630.","journal-title":"J Immunol Res"},{"issue":"2","key":"2292_CR146","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","volume":"83","author":"H Fang","year":"2016","unstructured":"Fang H, Shao S, Cao T, Lei J, Dang E, Zhang J, et al. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. J Dermatol Sci. 2016;83(2):116\u201323.","journal-title":"J Dermatol Sci"},{"issue":"8","key":"2292_CR147","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.4049\/jimmunol.1402688","volume":"194","author":"H Sadeghi","year":"2015","unstructured":"Sadeghi H, Lockmann A, Hund AC, Samavedam UK, Pipi E, Vafia K, et al. Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules. J Immunol. 2015;194(8):3656\u201363.","journal-title":"J Immunol"},{"issue":"2","key":"2292_CR148","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jid.2016.08.032","volume":"137","author":"S Tukaj","year":"2017","unstructured":"Tukaj S, Bieber K, Kleszczynski K, Witte M, Cames R, Kalies K, et al. Topically applied Hsp90 blocker 17AAG inhibits autoantibody-mediated blister-inducing cutaneous inflammation. J Invest Dermatol. 2017;137(2):341\u20139.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2292_CR149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070496","volume":"8","author":"S Tukaj","year":"2013","unstructured":"Tukaj S, Kleszczynski K, Vafia K, Groth S, Meyersburg D, Trzonkowski P, et al. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. PLoS ONE. 2013;8(7):e70496.","journal-title":"PLoS ONE"},{"issue":"12","key":"2292_CR150","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s001050051001","volume":"50","author":"W Kippes","year":"1999","unstructured":"Kippes W, Schmidt E, Roth A, Rzany B, Brocker EB, Zillikens D. Immunopathologic changes in 115 patients with bullous pemphigoid. Hautarzt. 1999;50(12):866\u201372.","journal-title":"Hautarzt"},{"key":"2292_CR151","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med. 2025;14(9):3026.","DOI":"10.3390\/jcm14093026"},{"issue":"7","key":"2292_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102852","volume":"20","author":"C Papara","year":"2021","unstructured":"Papara C, Zillikens D, Sadik CD, Baican A. MicroRNAs in pemphigus and pemphigoid diseases. Autoimmun Rev. 2021;20(7):102852.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2292_CR153","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"LS Chan","year":"2002","unstructured":"Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370\u20139.","journal-title":"Arch Dermatol"},{"issue":"4","key":"2292_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev. 2022;21(4):103036.","journal-title":"Autoimmun Rev"},{"key":"2292_CR155","doi-asserted-by":"crossref","unstructured":"van Beek N, Weidinger A, Schneider SW, Kleinheinz A, Glaser R, Holtsche MM, et al. Incidence of pemphigoid diseases in Northern Germany in 2016\u2014first data from the Schleswig\u2013Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol. 2021;35(5):1197\u2013202.","DOI":"10.1111\/jdv.17107"},{"issue":"9","key":"2292_CR156","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/eye.2012.119","volume":"26","author":"CF Radford","year":"2012","unstructured":"Radford CF, Rauz S, Williams GP, Saw VP, Dart JK. Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye. 2012;26(9):1199\u2013208.","journal-title":"Eye"},{"issue":"10","key":"2292_CR157","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41433-018-0155-7","volume":"32","author":"S Bobba","year":"2018","unstructured":"Bobba S, Devlin C, Di Girolamo N, Wakefield D, McCluskey P, Chan E, et al. Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. Eye. 2018;32(10):1636\u201343.","journal-title":"Eye"},{"issue":"9","key":"2292_CR158","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jdv.17397","volume":"35","author":"H Rashid","year":"2021","unstructured":"Rashid H, Lamberts A, Borradori L, Alberti-Violetti S, Barry RJ, Caproni M, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology\u2014part I. J Eur Acad Dermatol Venereol. 2021;35(9):1750\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2292_CR159","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","volume":"69","author":"MM Holtsche","year":"2018","unstructured":"Holtsche MM, Zillikens D, Schmidt E. Mucous membrane pemphigoid. Hautarzt. 2018;69(1):67\u201383.","journal-title":"Hautarzt"},{"issue":"1","key":"2292_CR160","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamadermatol.2021.4773","volume":"158","author":"N van Beek","year":"2022","unstructured":"van Beek N, Kridin K, Buhler E, Kochan AS, Stander S, Ludwig RJ, et al. Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol. 2022;158(1):84\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2292_CR161","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2017.05.016","volume":"77","author":"I Shimanovich","year":"2017","unstructured":"Shimanovich I, Nitz JM, Zillikens D. Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid. J Am Acad Dermatol. 2017;77(4):700-5 e3.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2292_CR162","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1902\/jop.2004.75.10.1302","volume":"75","author":"M Carrozzo","year":"2004","unstructured":"Carrozzo M, Cozzani E, Broccoletti R, Carbone M, Pentenero M, Arduino P, et al. Analysis of antigens targeted by circulating IgG and IgA antibodies in patients with mucous membrane pemphigoid predominantly affecting the oral cavity. J Periodontol. 2004;75(10):1302\u20138.","journal-title":"J Periodontol"},{"issue":"5","key":"2292_CR163","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1046\/j.1365-2133.2001.04471.x","volume":"145","author":"E Schmidt","year":"2001","unstructured":"Schmidt E, Skrobek C, Kromminga A, Hashimoto T, Messer G, Brocker EB, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol. 2001;145(5):778\u201383.","journal-title":"Br J Dermatol"},{"key":"2292_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00034","volume":"10","author":"M Kamaguchi","year":"2019","unstructured":"Kamaguchi M, Iwata H. The diagnosis and blistering mechanisms of mucous membrane pemphigoid. Front Immunol. 2019;10:34.","journal-title":"Front Immunol"},{"issue":"1","key":"2292_CR165","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/08916934.2011.606447","volume":"45","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012;45(1):55\u201370.","journal-title":"Autoimmunity"},{"issue":"11","key":"2292_CR166","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1167\/iovs.08-3345","volume":"50","author":"VP Saw","year":"2009","unstructured":"Saw VP, Dart RJ, Galatowicz G, Daniels JT, Dart JK, Calder VL. Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2009;50(11):5310\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"2292_CR167","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.2353\/ajpath.2009.090579","volume":"175","author":"VP Saw","year":"2009","unstructured":"Saw VP, Offiah I, Dart RJ, Galatowicz G, Dart JK, Daniels JT, et al. Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. Am J Pathol. 2009;175(6):2406\u201315.","journal-title":"Am J Pathol"},{"key":"2292_CR168","doi-asserted-by":"crossref","unstructured":"Goletz S, Probst C, Komorowski L, Schlumberger W, Fechner K, van Beek N, et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol. 2019;180(1):149\u201356.","DOI":"10.1111\/bjd.17202"},{"issue":"9","key":"2292_CR169","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/ced\/llae124","volume":"49","author":"X Li","year":"2024","unstructured":"Li X, Pas HH, Qian H, Rashid H, Horvath B, Yilmaz K, et al. Potential correlation between anti-laminin 332 autoantibodies and malignant tumours in anti-BP180-type mucous membrane pemphigoid. Clin Exp Dermatol. 2024;49(9):1075\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"9271","key":"2292_CR170","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","volume":"357","author":"CA Egan","year":"2001","unstructured":"Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850\u20131.","journal-title":"Lancet"},{"key":"2292_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250115","volume":"14","author":"S Patzelt","year":"2023","unstructured":"Patzelt S, Schmidt E. Autoimmunity against laminin 332. Front Immunol. 2023;14:1250115.","journal-title":"Front Immunol"},{"key":"2292_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.812627","volume":"12","author":"S Patzelt","year":"2021","unstructured":"Patzelt S, Pigors M, Steenbock H, Diel L, Boch K, Chakievska L, et al. Increased fibrosis in a mouse model of anti-Laminin 332 mucous membrane pemphigoid remains unaltered by inhibition of aldehyde dehydrogenase. Front Immunol. 2021;12:812627.","journal-title":"Front Immunol"},{"key":"2292_CR173","doi-asserted-by":"crossref","unstructured":"Murthy S, Patzelt S, Kunstner A, Busch H, Schmidt E, Sadik CD. Intravenous Ig ameliorates disease in a murine model of anti-laminin 332 mucous membrane pemphigoid. J Invest Dermatol. 2024;144(12):2671\u20132681.e1.","DOI":"10.1016\/j.jid.2024.02.038"},{"issue":"11","key":"2292_CR174","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","volume":"141","author":"S Murthy","year":"2021","unstructured":"Murthy S, Schilf P, Patzelt S, Thieme M, Becker M, Kroger L, et al. Dapsone suppresses disease in preclinical murine models of pemphigoid diseases. J Invest Dermatol. 2021;141(11):2587-95 e2.","journal-title":"J Invest Dermatol"},{"issue":"16","key":"2292_CR175","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1073\/pnas.93.16.8569","volume":"93","author":"JC Delgado","year":"1996","unstructured":"Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA. 1996;93(16):8569\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2292_CR176","doi-asserted-by":"publisher","first-page":"11579","DOI":"10.1073\/pnas.88.24.11579","volume":"88","author":"AR Ahmed","year":"1991","unstructured":"Ahmed AR, Foster S, Zaltas M, Notani G, Awdeh Z, Alper CA, et al. Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci USA. 1991;88(24):11579\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2292_CR177","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","volume":"35","author":"E Schmidt","year":"2021","unstructured":"Schmidt E, Rashid H, Marzano AV, Lamberts A, Di Zenzo G, Diercks GFH, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology\u2014part II. J Eur Acad Dermatol Venereol. 2021;35(10):1926\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2292_CR178","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","volume":"72","author":"DF Murrell","year":"2015","unstructured":"Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"2292_CR179","doi-asserted-by":"crossref","unstructured":"Patel PM, Jones VA, Murray TN, Amber KT. A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita. Am J Clin Dermatol. 2020;21(4):557\u201365.","DOI":"10.1007\/s40257-020-00513-3"},{"issue":"11","key":"2292_CR180","first-page":"1530","volume":"20","author":"SC Hofmann","year":"2022","unstructured":"Hofmann SC, Gunther C, Bockle BC, Didona D, Ehrchen J, Gaskins M, et al. S2k guideline for the diagnosis and treatment of mucous membrane pemphigoid. JDDG J Dtsch Dermatol Ges. 2022;20(11):1530\u201350.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"2292_CR181","unstructured":"Schmidt E, Lambert A, Marzano A, Rashid H, Di Zenzo G, Diercks G, et al. S3 guideline on the diagnosis and management of mucous membrane pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) Part II (in preparation)."},{"issue":"5","key":"2292_CR182","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/EJO.2011.6294","volume":"21","author":"MA El Darouti","year":"2011","unstructured":"El Darouti MA, Fakhry Khattab MA, Hegazy RA, Hafez DA, Gawdat HI. Pentoxifylline (anti-tumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid. Eur J Ophthalmol. 2011;21(5):529\u201337.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2292_CR183","first-page":"68","volume":"9","author":"JS Kennedy","year":"2010","unstructured":"Kennedy JS, Devillez RL, Henning JS. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol. 2010;9(1):68\u201370.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2292_CR184","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.oooo.2024.07.002","volume":"138","author":"G Setti","year":"2024","unstructured":"Setti G, Vaschieri C, Caramaschi S, Magnoni C, Consolo U, Bellini P. Anti-TNF-alpha induced mucous membrane pemphigoid-like disease. Oral Surg Oral Med Oral Pathol Oral Radiol. 2024;138(5):e95\u2013100.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"12","key":"2292_CR185","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","volume":"136","author":"S Sarny","year":"2018","unstructured":"Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. JAMA Ophthalmol. 2018;136(12):1420\u20132.","journal-title":"JAMA Ophthalmol."},{"key":"2292_CR186","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","volume":"27","author":"KM Burningham","year":"2022","unstructured":"Burningham KM, Cao J, Dominguez AR. Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate. JAAD Case Rep. 2022;27:67\u20139.","journal-title":"JAAD Case Rep"},{"key":"2292_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101104","volume":"22","author":"H James","year":"2021","unstructured":"James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22:101104.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"2292_CR188","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022;7(1):67.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2292_CR189","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2292_CR190","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022;81(12):1685\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2292_CR191","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s00415-023-11690-6","volume":"270","author":"C Louapre","year":"2023","unstructured":"Louapre C, Rosenzwajg M, Golse M, Roux A, Pitoiset F, Adda L, et al. A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis. J Neurol. 2023;270(9):4403\u201314.","journal-title":"J Neurol"},{"issue":"4","key":"2292_CR192","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295\u2013305.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2292_CR193","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jaad.2024.08.033","volume":"91","author":"R Xue","year":"2024","unstructured":"Xue R, Li G, Zhou Y, Wang B, Xu Y, Zhao P, et al. Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: a single center perspective-controlled trial. J Am Acad Dermatol. 2024;91(6):1113\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"2292_CR194","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3389\/fimmu.2017.01628","volume":"8","author":"K Bieber","year":"2017","unstructured":"Bieber K, Sun S, Witte M, Kasprick A, Beltsiou F, Behnen M, et al. Regulatory T cells suppress inflammation and blistering in pemphigoid diseases. Front Immunol. 2017;8:1628.","journal-title":"Front Immunol"},{"issue":"8","key":"2292_CR195","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","volume":"304","author":"P Quaglino","year":"2012","unstructured":"Quaglino P, Antiga E, Comessatti A, Caproni M, Nardo T, Ponti R, et al. Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. Arch Dermatol Res. 2012;304(8):639\u201345.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"2292_CR196","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","volume":"142","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu K, Ujiie H, Kobayashi I, Nishie W, Izumi K, Ito T, et al. Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J Allergy Clin Immunol. 2018;142(6):1818-30 e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2292_CR197","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/ced.13135","volume":"42","author":"T Gambichler","year":"2017","unstructured":"Gambichler T, Tsitlakidon A, Skrygan M, Hoxtermann S, Susok L, Hessam S. T regulatory cells and other lymphocyte subsets in patients with bullous pemphigoid. Clin Exp Dermatol. 2017;42(6):632\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2292_CR198","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/bjd\/ljae220","volume":"191","author":"V Hebert","year":"2024","unstructured":"Hebert V, Novarino J, Maho-Vaillant M, Perals C, Calbo S, Golinski ML, et al. The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris. Br J Dermatol. 2024;191(4):605\u201315.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2292_CR199","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000099585","volume":"214","author":"H Sugiyama","year":"2007","unstructured":"Sugiyama H, Matsue H, Nagasaka A, Nakamura Y, Tsukamoto K, Shibagaki N, et al. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology. 2007;214(3):210\u201320.","journal-title":"Dermatology"},{"issue":"12","key":"2292_CR200","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 2023;75(12):2185\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2292_CR201","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T Dorner","year":"2024","unstructured":"Dorner T, Kaul M, Szanto A, Tseng JC, Papas AS, Pylvaenaeinen I, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 2024;83(3):360\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2292_CR202","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2292_CR203","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/annrheumdis-2012-202775","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013;72(9):1461\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2292_CR204","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.jcjo.2022.11.011","volume":"59","author":"M Lin","year":"2024","unstructured":"Lin M, Boonsopon S, Manhapra A, Zhao T, Foster CS. Elevated serum BAFF in patients with ocular cicatricial pemphigoid. Can J Ophthalmol. 2024;59(2):e105\u201310.","journal-title":"Can J Ophthalmol"},{"issue":"12","key":"2292_CR205","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.jid.2024.02.038","volume":"144","author":"S Murthy","year":"2024","unstructured":"Murthy S, Patzelt S, Kunstner A, Busch H, Schmidt E, Sadik CD. Intravenous Ig ameliorates disease in a murine model of anti-laminin 332 mucous membrane pemphigoid. J Invest Dermatol. 2024;144(12):2671-81 e1.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2292_CR206","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ICO.0000000000003382","volume":"43","author":"N Jain","year":"2024","unstructured":"Jain N, Jakati S, Shanbhag SS, Basu S. Direct immunofluorescence findings and factors affecting conjunctival biopsy positivity in ocular mucous membrane pemphigoid. Cornea. 2024;43(2):159\u201365.","journal-title":"Cornea"},{"issue":"6","key":"2292_CR207","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/jop.12732","volume":"47","author":"I Shimanovich","year":"2018","unstructured":"Shimanovich I, Nitz JM, Witte M, Zillikens D, Rose C. Immunohistochemical diagnosis of mucous membrane pemphigoid. J Oral Pathol Med. 2018;47(6):613\u20139.","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"2292_CR208","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/jamadermatol.2022.5829","volume":"159","author":"K Kridin","year":"2023","unstructured":"Kridin K, van Beek N, Buhler E, Kochan AS, Ranjbar M, Beissert S, et al. Characteristics associated with refractory course, blindness, and treatment strategy-related outcomes in patients with mucous membrane pemphigoid. JAMA Dermatol. 2023;159(2):198\u2013203.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2292_CR209","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1172\/JCI118942","volume":"98","author":"Z Lazarova","year":"1996","unstructured":"Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest. 1996;98(7):1509\u201318.","journal-title":"J Clin Invest"},{"issue":"8","key":"2292_CR210","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","volume":"137","author":"EN Heppe","year":"2017","unstructured":"Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C, et al. Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol. 2017;137(8):1709\u201318.","journal-title":"J Invest Dermatol"},{"key":"2292_CR211","unstructured":"Patzelt SPM, Khilchenko S, Emtenani S, Kamaguchi M, Chakievska L, Bieber K, Cocchiaro P, Brandolini L, Aramini A, Allegretti M, Ludwig RJ, Schmidt E. Topical C5aR1 inhibition reduced clinical lesions in a preclinical model of mucous membrane pemphigoid. Exp Dermatol. 2025;34:e70025."},{"key":"2292_CR212","doi-asserted-by":"publisher","first-page":"adv40162","DOI":"10.2340\/actadv.v104.40162","volume":"104","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liu X, Ni J, Qi Y, Song Z, Piao Y. Successful treatment of mucous membrane pemphigoid with dupilumab: a case report. Acta Derm Venereol. 2024;104:adv40162.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"2292_CR213","first-page":"1113","volume":"20","author":"HS Raef","year":"2021","unstructured":"Raef HS, Elmariah SB. Successful treatment of brunsting-perry cicatricial pemphigoid with dupilumab. J Drugs Dermatol. 2021;20(10):1113\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2292_CR214","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1034\/j.1600-0625.2002.110505.x","volume":"11","author":"M Caproni","year":"2002","unstructured":"Caproni M, Calzolari A, Giomi B, Santucci M, Ficarra G, Fabbri P. IL-4, IL-5, TGF-beta1 and IFN-gamma mRNAs detected by a new in situ amplification system in cicatricial pemphigoid. Exp Dermatol. 2002;11(5):421\u20137.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2292_CR215","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, Czernik A, McLeod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46\u201352.","journal-title":"J Am Acad Dermatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02292-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:02:05Z","timestamp":1774072925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02292-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":215,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2292"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02292-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ES has scientific cooperations with Euroimmun, Incyte, Biotest, ArgenX, Dompe, Fresenius Medical Care, and Sanofi and received honoraria for speaking or consulting by Biotest, ArgenX, Fresenius Medical Care, Almirall, Chugai, and Sanofi. ES is an inventor in patents with Euroimmun and Dompe. NvB is an inventor in a patent with Euroimmun and received speaker honoraria from Fresenius Medical Care. MK has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors wrote the original draft as well as critically reviewed and edited the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}